tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Machida M et al. | Effect of temperature and hematocrit on plasma concentration of FK 506. | 1991 | Transplant. Proc. | pmid:1721266 |
| Kawauchi M et al. | Plasma level of FK 506 in newborn goats and infant baboons. | 1991 | Transplant. Proc. | pmid:1721267 |
| Iwasaki K et al. | Pharmacokinetic study of FK 506 in the rat. | 1991 | Transplant. Proc. | pmid:1721268 |
| Kay JE et al. | Uptake of FK 506 by lymphocytes and erythrocytes. | 1991 | Transplant. Proc. | pmid:1721269 |
| Jain AB et al. | Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721270 |
| O'Neill EA et al. | The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. | 1991 | Transplant. Proc. | pmid:1721298 |
| Nelson PA et al. | Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. | 1991 | Transplant. Proc. | pmid:1721299 |
| Dumont FJ et al. | Up-regulation of gene expression by FK 506. | 1991 | Transplant. Proc. | pmid:1721300 |
| Rao P et al. | Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. | 1991 | Transplant. Proc. | pmid:1721301 |
| Ishibashi M et al. | Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. | 1991 | Transplant. Proc. | pmid:1721330 |
| Kawauchi M et al. | Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. | 1991 | Transplant. Proc. | pmid:1721331 |
| Borg AJ and Kumagai M | FK 506 and xenogeneic human anti-porcine cellular reactivity. | 1991 | Transplant. Proc. | pmid:1721332 |
| Fung J et al. | A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. | 1991 | Transplant. Proc. | pmid:1721333 |
| Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721363 | |
| van Hoek B et al. | Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. | 1991 | Transplant. Proc. | pmid:1703343 |
| Jensen CW et al. | Pediatric renal transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721364 |
| McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
| Jordan ML et al. | FK 506 conversion of renal allografts failing cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721365 |
| Alessiani M et al. | Infections in adult liver transplant patients under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703345 |
| Offner G et al. | FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. | 1991 | Transplant. Proc. | pmid:1721366 |
| Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
| Scantlebury V et al. | New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. | 1991 | Transplant. Proc. | pmid:1721395 |
| Carroll PB et al. | FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. | 1991 | Transplant. Proc. | pmid:1721396 |
| Freise CE et al. | Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721397 |
| Eidelman BH et al. | Neurologic complications of FK 506. | 1991 | Transplant. Proc. | pmid:1721398 |
| Langrehr JM et al. | Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. | 1991 | Transplant. Proc. | pmid:1721425 |
| Takeda Y et al. | Effect of FK 506 on the survival of rat small bowel allografts. | 1991 | Transplant. Proc. | pmid:1721426 |
| Fukuzawa M et al. | Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. | 1991 | Transplant. Proc. | pmid:1721427 |
| Ogasa N et al. | Effect of FK 506 on growth of transplanted newborn rat intestine. | 1991 | Transplant. Proc. | pmid:1721428 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Michnick SW et al. | Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. | 1991 | Science | pmid:1709301 |
| Carroll PB et al. | The use of FK 506 in new-onset type I diabetes in man. | 1991 | Transplant. Proc. | pmid:1721458 |
| McCauley J et al. | FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. | 1991 | Transplant. Proc. | pmid:1721459 |
| Carrieri G et al. | Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. | 1991 | Transplant. Proc. | pmid:1721460 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Takada K et al. | Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. | 1991 | J. Pharmacobio-dyn. | pmid:1713626 |
| Thomson AW | The immunosuppressive macrolides FK-506 and rapamycin. | 1991 | Immunol. Lett. | pmid:1717376 |
| Takaya S et al. | Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1703691 |
| Steeves M et al. | In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. | 1991 | J. Pharm. Pharmacol. | pmid:1717676 |
| Hildebrandt A et al. | FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1703694 |
| Unmasking immunosuppression. | 1991 | Lancet | pmid:1717800 | |
| Ericzon BG et al. | Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. | 1991 | Transplant. Proc. | pmid:1703695 |
| Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
| Kumano K et al. | FK 506-induced nephrotoxicity in rats. | 1991 | Transplant. Proc. | pmid:1703696 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |